WHO Informal Consultation with VHPB
Geneva, Switzerland, May 13-14, 2002
- Meeting Programme -
Public health challenges for controlling HCV infection
Monday, May 13, 2002
Session 1 Opening and objectives
Chair: Andrι Meheus
09.00 - 09.30
- Welcome
- Introduction of the participants
- Objectives of the meeting:
- Review of the newest knowledge on hepatitis C virus infection and its epidemiology
- Discussion of prevention and control strategies for HCV infection
- Review of selected country experiences
- Recommendations on public health action in the prevention and control of HCV infection
- Review of the meeting programme
- Public health challenges for controlling HCV infection: an overview of the situation - Pre-meeting document 471 Kb (.pdf)
Session 2A HCV infection
Chair: Wolfgang Jilg & Daniel Shouval
09.30 - 10.00
The hepatitis C virus 950Kb (.pdf)
Peter Grob (Switzerland)
10.00 - 10.30
Human immune response to hepatitis C virus 893 Kb (.ppt)
Geert Leroux-Roels (Belgium)
10.30 - 11.00
Coffe break
11.00 - 11.30
Laboratory and clinical diagnosis of HCV infection 210 Kb (.pdf)
Jean-Michel Pawlotsky (France)
11.30 - 12.00
Natural history of HCV infection 1,092 Kb (.pdf)
Daniel Lavanchy (WHO, Switzerland)
12.00 - 13.30
Lunch
Session 3 Epidemiology of HCV infection
Chair: Paolo Bonanni & Alessandro Zanetti
13.30 - 14.00
Global epidemiology of HCV infection 1,065 Kb (.pdf)
Daniel Lavanchy (WHO, Switzerland)
14.00 - 14.30
How to collect and evaluate surveillance and epidemiologic data for hepatitis C 499 Kb (.ppt)
Miriam Alter (USA)
Session 5B Country reports
14.30 15.00
Health strategy on HCV in The Netherlands 423 Kb (.ppt)
Jan van Hattum (The Netherlands)
15.00 15.20
Coffee break
Session 4 Prevention and control of HCV infection
Chair: Yvan Hutin & Harold Margolis
15.20 15.50
Public health challenges for controlling HCV infection 107 Kb (.ppt)
Alessandro Zanetti (Italy)
15.50 16.20
Development of HCV vaccines: state of the art
Erik D'Hondt (Belgium)
16.20 16.50
Prevention of hepatitis C virus infection: achievement through integration into established prevention programmes 360 Kb (.ppt)
Harold Margolis (USA)
16.50 17.20
Integrating prevention, control, and therapy for viral hepatitis: the Canadian model 1,317 Kb (.ppt)
David Patrick (Canada)
17.20 17.50
HCV injecting drug users: developing indicators of prevalence and responses 1,299 Kb (.ppt)
Lucas Wiessing (EMCDDA, Portugal)
Tuesday, May 14, 2002
Session 2B HCV infection
Chair: Peter Grob & Daniel Lavanchy
09.00 - 09.30
Clinical manifestations of HCV infection 396 Kb (.ppt)
Daniel Shouval (Israel)
09.30 - 10.00
Hepatitis C: therapeutic options 1,781 Kb (.ppt)
Michael Manns (Germany)
10.00 - 10.30
Estimating the global burden of HCV infections associated with unsafe health care injections 408 Kb (.ppt)
Yvan Hutin (WHO, Switzerland)
10.30 - 10.50
Coffee break
Session 5B Country reports
Chair: Selim Badur & Nicole Guιrin
10.50 11.00
Hepatitis C infection in Turkey 393 Kb (.ppt)
Selim Badur (Turkey)
11.00 11.30
Epidemiology, prevention, and control programmes of hepatitis C in Egypt 901 Kb (.ppt)
Mostafa Mohamed (Egypt)
11.30 12.00
Surveillance of hepatitis C infections in France 211 Kb (.ppt)
Jean-Claude Desenclos (France)
12.00 12.30
Tackling the HCV epidemic in Switzerland 336 Kb (.pdf)
Francesco Negro (Switzerland)
12.30 - 14.00
Lunch
Session 6 Conclusions of the meeting
Chair: Johannes Hallauer & Michael Kew
14.00 - 15.30
Presentation of the VHPB meeting conclusions, including discussion (public health sector: information of the public, recommendations for testing, notification system, target groups; clinical and laboratory sector: collaboration with the public sector, finances)/amendments to existing recommendations (CDC, EASL, NIH, RKI, VHPB, WHO,
)
Johannes Hallauer (Germany) and Michael Kew (South Africa)
15.30
Closing of the meeting
